SG11201509985XA - Influenza virus reassortment - Google Patents
Influenza virus reassortmentInfo
- Publication number
- SG11201509985XA SG11201509985XA SG11201509985XA SG11201509985XA SG11201509985XA SG 11201509985X A SG11201509985X A SG 11201509985XA SG 11201509985X A SG11201509985X A SG 11201509985XA SG 11201509985X A SG11201509985X A SG 11201509985XA SG 11201509985X A SG11201509985X A SG 11201509985XA
- Authority
- SG
- Singapore
- Prior art keywords
- influenza virus
- virus reassortment
- reassortment
- influenza
- virus
- Prior art date
Links
- 241000712461 unidentified influenza virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16141—Use of virus, viral particle or viral elements as a vector
- C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832091P | 2013-06-06 | 2013-06-06 | |
| EP13179013 | 2013-08-01 | ||
| PCT/IB2014/062030 WO2014195920A2 (en) | 2013-06-06 | 2014-06-06 | Influenza virus reassortment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509985XA true SG11201509985XA (en) | 2016-01-28 |
Family
ID=48900885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509985XA SG11201509985XA (en) | 2013-06-06 | 2014-06-06 | Influenza virus reassortment |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10329537B2 (en) |
| EP (1) | EP3004332A2 (en) |
| JP (1) | JP2016521553A (en) |
| KR (1) | KR20160014657A (en) |
| CN (1) | CN105722976A (en) |
| AU (1) | AU2014276418A1 (en) |
| BR (1) | BR112015030582A2 (en) |
| CA (1) | CA2914604A1 (en) |
| HK (1) | HK1222882A1 (en) |
| MX (1) | MX2015016755A (en) |
| SG (1) | SG11201509985XA (en) |
| WO (1) | WO2014195920A2 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011056591A1 (en) | 2009-10-26 | 2011-05-12 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
| EP3022296B1 (en) * | 2013-07-15 | 2022-12-28 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| WO2016207853A2 (en) | 2015-06-26 | 2016-12-29 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| JP2019510481A (en) * | 2016-02-19 | 2019-04-18 | ウィスコンシン アルムニ リサーチ ファンデイション | Improved influenza B virus replication for vaccine development |
| CN109312310B (en) * | 2016-07-15 | 2022-08-02 | 一般财团法人阪大微生物病研究会 | Preparation method of reassortant influenza virus |
| CN108048476B (en) * | 2017-11-21 | 2020-09-08 | 浙江迪福润丝生物科技有限公司 | Method for preparing H9 subtype avian influenza vaccine strain for distinguishing immune animals and infected animals and application |
| CN108018300B (en) | 2017-11-21 | 2020-08-28 | 浙江迪福润丝生物科技有限公司 | H7 subtype avian influenza vaccine strain for distinguishing immune animals and infected animals as well as preparation method and application thereof |
| EP4151735A1 (en) * | 2018-03-21 | 2023-03-22 | Nature Technology Corporation | Viral and non-viral nanoplasmid vectors with improved production |
| US11241492B2 (en) | 2019-01-23 | 2022-02-08 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to genes in influenza viruses |
| US11851648B2 (en) | 2019-02-08 | 2023-12-26 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| EP4022046A2 (en) | 2019-08-27 | 2022-07-06 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized ha for replication in eggs |
| CN113527443B (en) * | 2020-04-16 | 2023-03-07 | 中国科学院微生物研究所 | Influenza A virus PB1 protein T cell epitope polypeptide segment and application thereof |
| JP2024514875A (en) * | 2021-04-15 | 2024-04-03 | バイオーケストラ カンパニー， リミテッド | Polynucleotides capable of enhancing protein expression and uses thereof |
| CN114058742B (en) * | 2022-01-18 | 2022-04-22 | 广州科方生物技术股份有限公司 | Primer probe composition, kit containing same and detection method thereof |
| WO2023234300A1 (en) * | 2022-05-31 | 2023-12-07 | Vlp Therapeutics Japan, Inc. | Modified vaccine design developments |
| CN116144612B (en) * | 2022-12-08 | 2023-11-10 | 广州医科大学附属第一医院（广州呼吸中心） | Recombinant influenza B virus and preparation method and application thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0832638B2 (en) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | Adjuvant formulation comprising submicron oil droplet emulsion |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| DE19612966B4 (en) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK cells and methods of propagating influenza viruses |
| DE19612967A1 (en) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| EP1878424A3 (en) | 1999-09-24 | 2008-04-09 | GlaxoSmithKline Biologicals S.A. | Novel vaccine |
| AU3604201A (en) | 2000-03-03 | 2001-09-12 | Chemo Sero Therapeut Res Inst | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| US20040096463A1 (en) | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
| WO2002074336A2 (en) | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| WO2005018539A2 (en) * | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| KR20070008625A (en) | 2004-04-05 | 2007-01-17 | 화이자 프로덕츠 인코포레이티드 | Microfluidized oil-in-water emulsions and vaccine compositions |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| CN101094915A (en) | 2004-05-20 | 2007-12-26 | 益得生物医学公司 | Process for the production of an influenza vaccine |
| JP5414178B2 (en) | 2004-12-23 | 2014-02-12 | メディミューン，エルエルシー | Non-tumorigenic MDCK cell line for virus propagation |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| BRPI0612268A2 (en) | 2005-06-21 | 2009-01-27 | Medimmune Vaccines Inc | Isolated nucleic acid, expression vector, Methods for producing a genomic influenza rna, for producing a recombinant influenza virus, for generating a recombinant negative strand segmented rna virus in cultured canine cells, and for generating infectious influenza viral particles in cells cultivated canines, cell and virus |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| CN101365480B (en) | 2005-11-01 | 2014-11-05 | 诺华疫苗和诊断有限两合公司 | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
| WO2007052061A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
| FR2896162B1 (en) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | EMULSION OIL IN THERMOREVERSIBLE WATER |
| WO2007124327A2 (en) | 2006-04-19 | 2007-11-01 | Medimmune Llc. | Methods and compositions for expressing negative-sense viral rna in canine cells |
| KR101151202B1 (en) | 2006-10-12 | 2012-06-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Vaccine comprising an oil in water emulsion adjuvant |
| WO2008068631A2 (en) | 2006-12-06 | 2008-06-12 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| EP2045323A1 (en) | 2007-10-05 | 2009-04-08 | Avir Green Hills Biotechnology Research Development Trade Ag | Linear expression constructs for production of influenza virus particles |
| KR101800245B1 (en) | 2009-05-21 | 2017-11-22 | 노파르티스 아게 | Reverse genetics using non-endogenous pol i promoters |
| US10272148B2 (en) * | 2009-06-24 | 2019-04-30 | Medicago Inc. | Chimeric influenza virus-like particles comprising hemagglutinin |
| CN102666860B (en) | 2009-07-31 | 2015-06-17 | 诺华股份有限公司 | Reverse genetics systems |
| PL2491117T3 (en) | 2009-10-20 | 2014-05-30 | Novartis Ag | Improved reverse genetics methods for virus rescue |
| EP2820126B1 (en) * | 2012-03-02 | 2017-05-17 | Seqirus UK Limited | Influenza virus reassortment |
| WO2014019990A1 (en) * | 2012-08-03 | 2014-02-06 | Sanofi Pasteur | Production of infectious influenza viruses |
-
2014
- 2014-06-06 EP EP14733369.4A patent/EP3004332A2/en not_active Withdrawn
- 2014-06-06 US US14/896,348 patent/US10329537B2/en active Active
- 2014-06-06 CN CN201480044797.3A patent/CN105722976A/en active Pending
- 2014-06-06 WO PCT/IB2014/062030 patent/WO2014195920A2/en active Application Filing
- 2014-06-06 CA CA2914604A patent/CA2914604A1/en not_active Abandoned
- 2014-06-06 SG SG11201509985XA patent/SG11201509985XA/en unknown
- 2014-06-06 BR BR112015030582A patent/BR112015030582A2/en not_active Application Discontinuation
- 2014-06-06 KR KR1020157035931A patent/KR20160014657A/en not_active Application Discontinuation
- 2014-06-06 MX MX2015016755A patent/MX2015016755A/en unknown
- 2014-06-06 AU AU2014276418A patent/AU2014276418A1/en not_active Abandoned
- 2014-06-06 JP JP2016517733A patent/JP2016521553A/en not_active Ceased
-
2016
- 2016-09-19 HK HK16110972.3A patent/HK1222882A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160122726A1 (en) | 2016-05-05 |
| AU2014276418A1 (en) | 2016-01-21 |
| WO2014195920A3 (en) | 2015-05-28 |
| CA2914604A1 (en) | 2014-12-11 |
| JP2016521553A (en) | 2016-07-25 |
| HK1222882A1 (en) | 2017-07-14 |
| MX2015016755A (en) | 2016-04-13 |
| WO2014195920A2 (en) | 2014-12-11 |
| KR20160014657A (en) | 2016-02-11 |
| BR112015030582A2 (en) | 2017-08-29 |
| EP3004332A2 (en) | 2016-04-13 |
| US10329537B2 (en) | 2019-06-25 |
| CN105722976A (en) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222882A1 (en) | Influenza virus reassortment | |
| IL276210B1 (en) | Mers-cov vaccine | |
| HK1218511A1 (en) | Influenza b virus reassortment | |
| IL241881B (en) | Composition comprising at least two influenza a virus-neutralizing-binding molecules | |
| HK1223110A1 (en) | Influenza virus vaccines and uses thereof | |
| HK1220163A1 (en) | Sprayer | |
| ZA201508642B (en) | Malaria vaccine | |
| GB201310432D0 (en) | Virus Production | |
| EP2974740A4 (en) | Hepatitis b vaccine | |
| EP3063273B8 (en) | Influenza virus vector for virotherapy | |
| GB201313201D0 (en) | Virus Detection | |
| HK1223644A1 (en) | Semi-live respiratory syncytial virus vaccine | |
| HK1217638A1 (en) | Influenza virus reassortment | |
| HK1217206A1 (en) | Vaccine | |
| HK1223643A1 (en) | Semi-live respiratory syncytial virus vaccine | |
| IL227462A0 (en) | Sprayer | |
| GB201301119D0 (en) | Viral vaccines | |
| HK1219904A1 (en) | Novel vaccines against multiple subtypes of dengue virus | |
| GB201304827D0 (en) | Infulenza virus reassortment | |
| GB201314063D0 (en) | Virus | |
| GB201306812D0 (en) | Virus | |
| AU2013905065A0 (en) | Viral vaccine | |
| AU2013905043A0 (en) | Viral vaccine | |
| AU2013904384A0 (en) | Viral vaccine | |
| FR3005265B3 (en) | REASSORTING THE INFLUENZA VIRUS |